Literature DB >> 15951873

Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment.

Mohammad Z Zailaie1.   

Abstract

OBJECTIVE: Limited studies have shown that treatment of cells with aspirin modulates their cytokine production. Consequently, the aim of the present study is to investigate the pattern of important proinflammatory cytokines production by stimulated peripheral blood mononuclear cells (PBMC) from patients with active vitiligo following long-term treatment with low-dose oral aspirin.
METHODS: The study was conducted at the Vitiligo Unit, King Abdul-Aziz University Medical Center, Jeddah, Kingdom of Saudi Arabia between March and October 2003. Thirty-two patients (18 females and 14 males) with non-segmental vitiligo were divided into 2 equal groups, one group received a daily single dose of oral aspirin (300 mg) and the other group received placebo for a period of 12 weeks. The concentrations of interleukin (IL)-1beta, IL-6, IL-8 and tumor necrosis factor-alpha (TNF-alpha) were determined in the supernatant of isolated cultured PMBC after being stimulated with bacterial lipopolysaccharide (LPS), before the start of aspirin treatment and at end of treatment period. Cytokine levels were measured using the quantitative sandwich enzyme-linked immunosorbent assay (ELISA) technique, utilizing commercially available kits.
RESULTS: The proinflammatory cytokine production by the PBMC of patients with active vitiligo was significantly increased compared to normal controls. Thus, the relative percentage increase in the production of IL-1beta, IL-6, IL-8 and TNF-alpha was: 39.4%, 110.5% (p<0.05), 91.5% (p<0.01), and 37% (p<0.05). At the end of treatment, proinflammatory cytokine production in the aspirin-treated group of active vitiligo patients was significantly decreased compared to the placebo group. Thus, the relative percentage decrease in the production of IL-1beta IL-6, IL-8 and TNF-alpha was: 42.5%, 45.2% (p<0.05), 30.8% (p<0.01), and 50.6% (p<0.05). The vitiligo activity was arrested in all aspirin-treated patients, while 2 patients demonstrated significant repigmentation.
CONCLUSION: Chronic administration of low-dose oral aspirin can down-regulate the PBMC proinflammatory cytokine production in active vitiligo with concomitant arrest of disease activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951873

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  6 in total

1.  Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients.

Authors:  Suman Singh; Usha Singh; S S Pandey
Journal:  Indian J Dermatol       Date:  2012-01       Impact factor: 1.494

2.  Aspirin induces Nrf2-mediated transcriptional activation of haem oxygenase-1 in protection of human melanocytes from H2 O2 -induced oxidative stress.

Authors:  Zhe Jian; Lingzhen Tang; Xiuli Yi; Bangmin Liu; Qian Zhang; Guannan Zhu; Gang Wang; Tianwen Gao; Chunying Li
Journal:  J Cell Mol Med       Date:  2016-03-10       Impact factor: 5.310

3.  Effects of a Traditional Caraway Formulation on Experimental Models of Vitiligo and Mechanisms of Melanogenesis.

Authors:  Abudujilili Abuduaini; Xueying Lu; Deng Zang; Tao Wu; Haji Akbar Aisa
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-19       Impact factor: 2.629

4.  Association Among MIF, IFIH1, and IL6 Gene Polymorphisms and Non-Segmental Vitiligo in a Chinese Han Population.

Authors:  Danfeng Wang; Shuhui Min; Xiao Lin; Guan Jiang
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-10

5.  Whole Transcriptome Analysis (RNA Sequencing) of Peripheral Blood Mononuclear Cells of Vitiligo Patients.

Authors:  E Reimann; K Kingo; M Karelson; P Reemann; E Vasar; H Silm; S Kõks
Journal:  Dermatopathology (Basel)       Date:  2014-01-09

Review 6.  Research Progress on Targeted Antioxidant Therapy and Vitiligo.

Authors:  Jingzhan Zhang; Wen Hu; Peng Wang; Yuan Ding; Hongjuan Wang; Xiaojing Kang
Journal:  Oxid Med Cell Longev       Date:  2022-03-14       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.